Ligand Pharmaceuticals has been granted a patent for acetal and cyclic acetal compounds with liver-targeting properties. The compounds, compositions, and their uses are disclosed in the patent, with a specific compound structure outlined in Claim 1. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11970482B2) discloses a compound with a specific chemical structure as defined in Formula I. The compound can have various configurations with defined 1,3-cis-stereochemistry, and different substituents on the alkyl groups R1, R2, R3, and R7. These substituents include functional groups like halo, cyano, hydroxyl, alkylthio, and nitro, among others. The patent also covers pharmaceutical compositions containing the disclosed compound for inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis.
Furthermore, the patent encompasses methods of inhibiting HMG-CoA reductase by administering the compound to individuals requiring such treatment. The compound's structure allows for flexibility in the alkyl and heterocyclyl groups, providing potential variations in the molecule's properties and interactions. The pharmaceutical compositions mentioned in the patent include the compound of interest along with suitable excipients for effective delivery and therapeutic outcomes. This patent highlights the potential for developing novel therapies targeting HMG-CoA reductase, a crucial enzyme in cholesterol metabolism, using the disclosed compound and its derivatives.
To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
